Last reviewed · How we verify
SPI-1005
At a glance
| Generic name | SPI-1005 |
|---|---|
| Also known as | ebselen, 200 mg Ebselen |
| Sponsor | Sound Pharmaceuticals, Incorporated |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Upper respiratory tract infection
- Blood triglycerides increased
- Gamma-glutamyltransferase increased
- Alanine aminotransferase increased
Key clinical trials
- SPI-1005 for the Treatment of Meniere's Disease (Open Label) (PHASE3)
- SPI-1005 in Adults Receiving Cochlear Implant (PHASE2)
- SPI-1005 for Prevention and Treatment of Tobramycin Induced Ototoxicity (PHASE2)
- SPI-1005 for the Treatment of Meniere's Disease (PHASE3)
- SPI-1005 Treatment in Severe COVID-19 Patients (PHASE2)
- SPI-1005 Treatment in Moderate COVID-19 Patients (PHASE2)
- SPI-1005 for the Treatment of Patients With Meniere's Disease (PHASE2)
- IMPase in Treatment-resistant Depression (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SPI-1005 CI brief — competitive landscape report
- SPI-1005 updates RSS · CI watch RSS
- Sound Pharmaceuticals, Incorporated portfolio CI